April 22nd 2024
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell Lymphoma
February 24th 2021For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.
Read More
Axi-Cel Shows Activity in Relapsed/Refractory DLBCL Regardless of Chemo Sensitivity
February 22nd 2021Data from patients with relapsed/refractory diffuse large B-cell lymphoma treated with axicabtagene ciloleucel showed that post-chimeric antigen receptor T outcomes may not correlate with responsiveness observed with treatment received immediately prior.
Read More
Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs
January 4th 2021During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.
Read More
Novel Bispecific Antibody Induces Encouraging Activity in B-Cell NHL
December 28th 2020In an interview with Targeted Oncology, Rajat Bannerji, MD, PhD, discussed the early and encouraging findings from a novel bispecific antibody for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
Read More
CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications
December 26th 2020Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.
Read More
Rolling BLA Submission Initiated for Cilta-Cel in R/R Multiple Myeloma
December 21st 2020Rolling submission has been initiated for a Biologics License Application, submitting data to the FDA for the potential approval of ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma.
Read More
Novel CAR Approach Overcomes Resistance in CD58-Mutant Large B-Cell Lymphoma
December 5th 2020Early data in mouse models have demonstrated that the novel approach of providing CD2 costimulation to CAR T cells in trans could reeestablish the efficacy of treatment in patients with CD58 mutations
Read More
First-In-Human Trial Shows Responses With Off-the-Shelf CAR T-Cell Therapy in Myeloma
December 5th 2020The off-the-shelf CAR T-cell therapy ALLO-715, which targets BCMA, demonstrated responses as treatment of patients with heavily pretreated relapsed/refractory multiple myeloma in a first-in-human clinical trial.
Read More
Novel Engineered CAR T Cells Show Early Promise in CD19+ B-Cell Malignancies
October 23rd 2020Chimeric antigen receptor T-cell therapy with the novel agent CTX110 showed promising early efficacy and safety as treatment of patients with relapsed or refractory CD19-positive B-cell malignancies who were treated in the phase 1 CARBON clinical trial.
Read More
FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
October 6th 2020The FDA granted Orphan Drug designation to the humanized anti-claudin18.2 autologous chimeric antigen receptor T-cell agent, CT041, for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma.
Read More
Expert Recognizes Major Advances in Field During Childhood Cancer Awareness Month
September 26th 2020In an interview with Targeted Oncology, Tanja Gruber, MD, PhD, discussed the advances she has observed in recent years for the treatment of pediatric patients, including the evolving role of CAR T-cell therapy.
Read More
CAR T-Cell Data Call for New Strategies in Treatment of Multiple Myeloma
September 15th 2020During a presentation at the 2020 Society of Hematologic Oncology Virtual Annual Meeting, Andrzej Jakubowiak, MD, PhD, reviewed clinical trials of CAR T-cell therapy in multiple myeloma and the emergence of CAR T cells against SMALF7, GPRC5D, and CD229.
Read More
Early Study Shows Feasibility of Single Vector Multiplexed shRNA for CAR T Cells
September 4th 2020In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple genes in chimeric antigen receptor T cells when used as treatment of patients with cancer.
Read More
Clinical Characteristics of DLBCL May Predict Outcomes for Patients Receiving CAR T Cells
August 24th 2020A single-center experience demonstrated that certain pre- and post-treatment characteristics may predict outcomes for patients with diffuse large B-cell lymphoma following treatment with a chimeric antigen receptor T-cell therapy.
Read More
Humanized CD19 CAR T-Cell Therapy Shows Early Promise as Treatment of Hematologic Malignancies
August 18th 2020An investigator-initiated trial of a humanized CD19-directed chimeric antigen receptor T-cell therapy has been completed, demonstrating the therapy may be a safe and effective treatment for patients with hematologic malignancies.
Read More
Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma
August 6th 2020"These data are significant, as they demonstrate that CAR T-cell therapy may be a safe and effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen."
Read More
Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point
August 4th 2020Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
Read More